fazarabine has been researched along with Neutropenia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ames, MM; Erlichman, C; Fitch, TR; Goldberg, RM; Kuffel, MJ; Reid, JM; Rubin, J; Sloan, JA | 1 |
| Ben-Baruch, N; Cowan, KH; Fine, R; Ford, H; Kelley, JA; Surbone, A; Thomas, RV | 1 |
2 trial(s) available for fazarabine and Neutropenia
| Article | Year |
|---|---|
Phase I and pharmacological trial of fazarabine (Ara-AC) with granulocyte colony-stimulating factor.
Topics: Adult; Antineoplastic Agents; Azacitidine; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Metabolic Clearance Rate; Nausea; Neoplasms; Neutropenia | 1997 |
Phase I and pharmacokinetic study of arabinofuranosyl-5-azacytosine (fazarabine, NSC 281272).
Topics: Adult; Aged; Antineoplastic Agents; Azacitidine; Clinical Trials as Topic; Drug Administration Schedule; Drug Evaluation; Female; Humans; Leukopenia; Male; Middle Aged; Neoplasms; Neutropenia; Thrombocytopenia | 1990 |